Research has shed light on the intricate mechanisms of insulin production in fruit flies, revealing surprising parallels with ...

a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential to enhance important facets of obesity treatment while achieving significant weight loss.

Skye Bioscience (SKYE) enters 2025 positioned to announce Phase 2 data for nimacimab, a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential ...